This trial is testing a new type of catheter to see if it is safe and effective for people with heart failure who haven't responded well to other treatments.
- Acute Heart Failure
2 Primary · 0 Secondary · Reporting Duration: baseline [pre intervention] and accumulated through 24 hours [T=0-24 hours]
Awards & Highlights
1 Treatment Group
1 of 1
15 Total Participants · 1 Treatment Group
Primary Treatment: Doraya catheter · No Placebo Group · N/A
Who is running the clinical trial?
Age 18 - 85 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are individuals over the age of 35 eligible to participate in this scientific experiment?
"As per the requirements, only those aged 18 and over but below 85 are eligible to take part in this medical experiment." - Anonymous Online Contributor
What is the aggregate size of this medical experiment's cohort?
"Affirmative. Clinicaltrials.gov attests to this medical trial being open for recruitment, which began on May 23rd 2022 and has been refreshed as recently as July 10th 2022. There is a need to identify 15 participants from 5 different sites." - Anonymous Online Contributor
Is this research endeavor actively accepting participants?
"Affirmative. According to the materials on clinicaltrials.gov, this medical trial posted in May of 2022 is actively recruiting participants. All together, 15 people need to be enrolled from 5 distinct sites." - Anonymous Online Contributor
Which demographics are most advantageous for this clinical trial?
"Applicants aged 18 to 85 suffering from acute decompensated heart failure (ADHF) are welcome to join this medical trial. Candidates must also meet the following prerequisites: a hospitalisation with ADFH as primary diagnosis, NT-proBNP or BNP levels of at least 1600 pg/m and 400pg/mL respectively, clear signs of fluid overload, and an insufficient reaction to IV diuretics." - Anonymous Online Contributor